KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial.

Hermine I Brunner, Ekaterina Alexeeva, Marcia Bandeira, Ruy Carrasco, Jeffrey Chaitow, Peter Chiraseveenuprapund, Tracy V Ting, Muferet Erguven, Beth Gottlieb, Sheila Knupp Oliveira, Pooja N Patel, Seza Ozen, Claudia Saad Magalhaes, Inmaculada Calvo Penadés, David Gruben, Rebecca Germino, Holly B Posner, Lori Stockert, Alberto Martini, Daniel J Lovell, Nicolino Ruperto, Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)

Arthritis Rheumatol 78(3) 752-762

PMID41169192
PMCIDPMC12991914
DOI10.1002/art.43428
发表日期2025-10-31
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图;Figure 3:非 KM 图;Figure 4:非 KM 图;Figure 5:AI 判定为 other。
摘要

摘要

OBJECTIVE: Juvenile idiopathic arthritis (JIA) is associated with impaired overall health-related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient-reported outcomes (PROs) in patients with JIA. METHODS: This was a post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled withdrawal trial (NCT02592434) in patients with JIA. In the open-label phase (part 1; weeks 0-18), patients received body weight-based doses of tofacitinib. During the double-blind phase (part 2; weeks 18-44), responders (per JIA-American College of Rheumatology 30 response criteria) were randomized 1:1 to continue tofacitinib or switch to placebo for up to 26 weeks. Assessed PROs included the validated parent and/or legal guardian versions of the Childhood Health Assessment Questionnaire for evaluation of disability, arthritis pain, overall well-being, and the Child Health Questionnaire (CHQ). RESULTS: Overall, 225 patients were enrolled and received open-label tofacitinib in part 1, and 173 patients were randomized in part 2. During part 1, least-squares (LS) mean (SE) disability, arthritis pain, and overall well-being scores numerically improved from mean 1.04 (SE 0.05), mean 5.53 (SE 0.20), and mean 5.07 (SE 0.20) at baseline to mean 0.57 (SE 0.05), mean 2.46 (SE 0.18), and mean 2.47 (SE 0.18) at week 18, respectively. LS mean (SE) CHQ physical summary and psychological summary scores numerically improved from mean 29.51 (SE 1.15) and mean 47.24 (SE 0.85) at baseline to mean 42.70 (SE 0.98) and mean 51.53 (SE 0.80) at week 18, respectively. Improvements were generally maintained to week 44 in part 2. CONCLUSION: Tofacitinib improved a range of PROs in patients with JIA, suggesting potential HRQoL benefits.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1LS mean (±SE) Childhood Health Assessment Questionnaire‐Disability Index scores over time in patients with juvenile idiopathic arthritis treated with tofacitinib in part 1 and tofacitinib or placebo in part 2 (overall population). Analyses were based on observed data; missing values were not imputed. Horizontal dashed lines represent mean Childhood Health Assessment Questionnaire‐Disability Index scores for patients with mild, mild‐to‐moderate, and moderate disability, which have been previously reported. 28 Vertical dashed line represents randomization (patients meeting the juvenile idiopathic arthritis American College of Rheumatology 30 response criteria randomized 1:1 to continue tofacitinib or switch to placebo for up to an additional 26 weeks). Median and interquartile range values for Childhood Health Assessment Questionnaire‐Disability Index are summarized in Supplementary Table 3 ; no significant differences in the distributions between the treatment arms were observed during part 2. LS, least‐squares.
非 KM Figure
Figure 2LS mean (±SE) arthritis pain (Childhood Health Assessment Questionnaire‐Discomfort Index) scores over time in patients with juvenile idiopathic arthritis treated with tofacitinib in part 1 and tofacitinib or placebo in part 2 (overall population). * P < 0.05 vs placebo. Analyses were based on observed data; missing values were not imputed. Dashed line represents randomization (patients meeting the juvenile idiopathic arthritis American College of Rheumatology 30 response criteria randomized 1:1 to continue tofacitinib or switch to placebo for up to an additional 26 weeks). Median and interquartile range values for arthritis pain (Childhood Health Assessment Questionnaire‐Discomfort Index) scores are summarized in Supplementary Table 3 ; significant differences ( P < 0.05) in the distributions were observed between the treatment arms at week 32. LS, least‐squares. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.43428/abstract .
非 KM Figure
Figure 3LS mean (±SE) patient overall well‐being scores over time in patients with juvenile idiopathic arthritis treated with tofacitinib in part 1 and tofacitinib or placebo in part 2 (overall population). * P < 0.05 vs placebo. Analyses were based on observed data; missing values were not imputed. Dashed line represents randomization (patients meeting the juvenile idiopathic arthritis American College of Rheumatology 30 response criteria randomized 1:1 to continue tofacitinib or switch to placebo for up to an additional 26 weeks). Median and interquartile range values for patient overall well‐being are summarized in Supplementary Table 3 ; no significant differences in the distributions were observed between the treatment arms during part 2. LS, least‐squares. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.43428/abstract .
非 KM Figure
Figure 4(A) LS mean (±SE) Child Health Questionnaire physical summary and Child Health Questionnaire psychosocial summary scores and (B) LS mean Child Health Questionnaire health concept scores at baseline and at the end of part 1 and part 2 in patients with juvenile idiopathic arthritis treated with tofacitinib in part 1 and tofacitinib or placebo in part 2 (overall population). Analyses were based on observed data; missing values were not imputed. Dashed line represents randomization (patients meeting the juvenile idiopathic arthritis American College of Rheumatology 30 response criteria randomized 1:1 to continue tofacitinib or switch to placebo for up to an additional 26 weeks). Median and interquartile range values for Child Health Questionnaire physical summary and psychosocial summary are summarized in Supplementary Table 3 ; no significant differences in the distributions between the treatment arms was observed during part 2. N values, medians, and interquartile range values for Child Health Questionnaire health concept scores are summarized in Supplementary Table 4 . LS, least‐squares; PhS, physical summary; PsS, psychosocial summary. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.43428/abstract .
非 KM Figure
Figure 5LS mean (±SE) duration of morning stiffness (minutes) in patients with juvenile idiopathic arthritis treated with tofacitinib in part 1 and tofacitinib or placebo in part 2 (overall population). * P < 0.05 vs placebo. Analyses were based on observed data; missing values were not imputed. Dashed line represents randomization (patients meeting the juvenile idiopathic arthritis American College of Rheumatology 30 response criteria randomized 1:1 to continue tofacitinib or switch to placebo for up to an additional 26 weeks). Median and interquartile range values for the duration of morning stiffness are summarized in Supplementary Table 3 ; significant differences ( P < 0.05) in the distributions were observed between the treatment arms at weeks 28 and 40. LS, least‐squares. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.43428/abstract .
非 KM Figure